北京德恒律师事务所 关于西安蓝晓科技新材料股份有限公司 2021 年限制性股票激励计划授予价格调整、首 次授予部分限制性股票第三个归属期及预留授 予部分第二个归属期归属条件成就暨部分限制 性股票作废相关事宜的法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 | 一、本次调整、本次归属的批准与授权 | 4 | | --- | --- | | 二、本次调整的具体情况 | 7 | | 三、本次归属的具体情况 | 8 | | 四、本次作废的具体情况 | 13 | | 五、结论性意见 | 13 | 关于西安蓝晓科技新材料股份有限公司 2021 年限制性股票激励计划授予价格调整、 首次授予部分限制性股票第三个归属期及预留授予部分第二个归属期 北京德恒律师事务所 归属条件成就暨部分限制性股票作废相关事宜的法律意见 释 义 在本法律意见中，除非文义另有所指，下列词语具有下述涵义： | 德恒/本所 | 指 | 北京德恒律师事务所 | | --- | --- | --- | | 公司/蓝晓科技 | 指 | 西安蓝晓科技新材料股份有 ...

国信证券股份有限公司 关于西安蓝晓科技新材料股份有限公司 募投项目结项并将结余募集资金 永久补充流动资金的核查意见 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号—保荐业务》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等有关法律法 规和规范性文件的要求，国信证券股份有限公司（简称"国信证券"或"保荐机 构"）作为西安蓝晓科技新材料股份有限公司（简称"蓝晓科技"或"公司"）的 持续督导保荐机构，对公司部分募投项目结项并将结余募集资金永久补充流动资 金事项进行了审慎核查，核查的具体情况如下： 一、募集资金及募投项目的基本情况 （一）募集资金的基本情况 经中国证券监督管理委员会证监许可〔2023〕 628 号文核准，并经深圳证券 交易所同意，本公司由主承销商国信证券股份有限公司采用公开发行方式，向不 特定对象发行 546.0645 万张可转换公司债券，每张面值 100 元，共计募集资金 54,606.45 万元。扣除承销费和保荐费 491.46 万元后的募集资金为人民币 54,114.99 万元，已由主承销商国 ...

Core Viewpoint - The company has announced the conclusion of two fundraising projects and plans to permanently allocate the remaining funds to support its daily operational activities [1] Group 1: Fundraising Projects - The company held its 11th meeting of the 5th Board of Directors on January 9, 2026, where it approved the conclusion of the "New Energy Metal Adsorption Separation Technology R&D Center Project" and the "New Energy Metal Adsorption Separation Technology Marketing and Service Center Construction Project" [1] - As of December 31, 2025, the total remaining fundraising amount for the two projects is estimated at 79.4063 million yuan, subject to final confirmation based on actual bank account balances on the transfer date [1] Group 2: Fund Allocation - The remaining funds will be permanently allocated to supplement the company's working capital, which is related to its main business operations [1] - The company will maintain the fundraising account to settle any outstanding contractual payments before closing the account and terminating the fundraising supervision agreement [1]

| 证券代码：300487 | 证券简称：蓝晓科技 | 公告编号：2026-006 | | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转02 | | 西安蓝晓科技新材料股份有限公司 关于募投项目结项并将结余募集资金永久补充流动资 金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （一）募集资金的基本情况 经中国证券监督管理委员会《关于同意西安蓝晓科技新材料股份有限公司向 1 不特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕628 号）核准， 并经深圳证券交易所同意，本公司于 2023 年 4 月 17 日向不特定对象发行了 546.0645 万张可转换公司债券，每张面值 100 元，共计募集资金 546,064,500.00 元，扣除承销及保荐费用 4,914,580.50 元后的募集资金为 541,149,919.50 元，已 由主承销商国信证券股份有限公司于 2023 年 4 月 21 日汇入本公司募集资金监管 账户。上述募集资金到位情况业经致同会计师事务所（特殊普通合伙）验证，并 由其出具《验 ...

| 证券代码：300487 | 证券简称：蓝晓科技 | | 公告编号：2026-007 | | --- | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转 | 02 | | 西安蓝晓科技新材料股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东会届次：2026 年第一次临时股东会。 2．股东会的召集人：董事会 3．经公司第五届董事会第十一次会议审议通过，决定召开 2026 年第一次临时股东 会，本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4．会议时间： （1）现场会议时间：2026 年 1 月 29 日 14:00:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 1 月 29 日 9:15-9:25，9:30-11:3 ...

| 证券代码：300487 | 证券简称：蓝晓科技 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：123195 | 债券简称：蓝晓转02 | | 西安蓝晓科技新材料股份有限公司 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西安蓝晓科技新材料股份有限公司（以下简称"公司"或"蓝晓科技"）第五 届董事会第十一次会议通知和议案等材料已于 2026 年 1 月 4 日以电子邮件、书 面送达等方式发送至各位董事，并于 2026 年 1 月 9 日在公司会议室召开会议。 本次会议应出席董事 9 人，实际到会 9 人，公司部分高级管理人员参加了会议。 会议由董事长高月静女士主持。会议符合《中华人民共和国公司法》（以下简 称《公司法》）及《公司章程》的有关规定。会议审议通过了如下决议： 一、审议通过《关于作废2021年限制性股票激励计划部分已授予尚未归属 的限制性股票的议案》 鉴于2021年限制性股票激励计划中首次授予部分4名激励对象因个人原因离 职，1名激励对象因年度个人评价结果不合格，预留授 ...

本次首次授予部分第三个归属期归属的 312 名激励对象及预留授予部分第 二个归属期归属的 86 名激励对象，符合《公司法》《证券法》等法律、法规和 规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》 等法律、法规和规范性文件规定的激励对象条件，符合本次激励计划规定的激励 对象范围，其作为公司本次激励计划激励对象的主体资格合法、有效，激励对象 获授限制性股票的归属条件已成就。 综上，董事会薪酬与考核委员会一致同意 2021 年限制性股票激励计划首次 授予部分第三个归属期及预留授予部分第二个归属期归属名单。 西安蓝晓科技新材料股份有限公司 董事会薪酬与考核委员会关于 2021 年限制性股票激励计划 首次授予部分第三个归属期及预留授予部分第二个归属期 归属名单的核查意见 西安蓝晓科技新材料股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会依据《公司法》《证券法》《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规 则》"）、《深圳证券交易所创业板上市公司自律监管指南第 1 号—业务办理》 和《公司章程》等相关规定，对公司 20 ...

Core Insights - The Chinese nanosphere industry is experiencing rapid growth, with a projected market size of approximately 4.236 billion yuan in 2024, representing a year-on-year increase of 5.40% [1][7]. Industry Overview - Nanospheres are micron-sized spheres with nanoscale pore structures, characterized by high specific surface area and unique physical and chemical properties. They are widely used in drug delivery, liquid crystal displays, bi separation, medical diagnostics, and optoelectronic materials [2][4]. - The primary materials for nanospheres are classified into natural biomaterials (such as chitosan and collagen) and synthetic polymers (like PLGA and PVA) [2]. Nanosphere Classification - Nanospheres can be categorized based on preparation methods, including ion crosslinking, emulsion-solvent evaporation, and microfluidic technology, each with distinct principles, applicable materials, and performance characteristics [4]. Industry Chain - The upstream of the nanosphere industry includes raw materials such as chitosan, starch, cellulose, and various polymers. The midstream involves the production and manufacturing of nanospheres, while the downstream applications span drug delivery, bi separation, in vitro diagnostics, LCD spacers, conductive materials, and light diffusion films [5][6]. Market Size - The Chinese nanosphere industry is on a growth trajectory, with a market size expected to reach approximately 4.236 billion yuan in 2024, marking a 5.40% increase from the previous year [1][7]. Key Companies - Suzhou Nanwei Technology Co., Ltd. is recognized as the industry leader, leveraging proprietary technologies for precise control over sphere size and surface properties. In the first three quarters of 2025, the company reported revenues of 671 million yuan, a 22.01% increase year-on-year [8][9]. - Xian Lanyao Technology Co., Ltd. is a leading player in the adsorption separation materials sector, focusing on life sciences. The company reported revenues of 193 million yuan in the first three quarters of 2025, reflecting a 2.20% year-on-year growth [10]. Industry Development Trends 1. **Technological Innovation**: The preparation technology for nanospheres is advancing towards ultra-high precision, functional integration, and green transformation, with a focus on AI-assisted design and biodegradable materials [11]. 2. **Diverse Application Demand**: The biopharmaceutical sector remains the core growth area for nanospheres, with increasing demand in electronic displays and environmental applications, leading to a surge in market demand [12]. 3. **Domestic Substitution**: The market is transitioning from foreign monopoly to rapid growth of local enterprises, with domestic leaders like Nanwei Technology gaining market share due to competitive pricing and technological advantages [12].

Group 1: Small Nucleic Acid Drugs - Small nucleic acid drugs, primarily SiRNA and ASO, are entering a rapid growth phase from technological breakthroughs to large-scale commercialization [2] - The global market for small nucleic acid drugs grew from $0.1 billion in 2016 to $3.25 billion in 2021, with a compound annual growth rate (CAGR) of 217.8% [2] - It is projected that the global oligonucleotide drug market will exceed $15 billion by 2026, with a CAGR of 35% from 2020 to 2025 [2] Group 2: Blue Sky Technology - Blue Sky Technology has established a comprehensive "synthesis-purification" supply capability for small nucleic acids (siRNA/ASO) and peptide drugs [3] - The company has developed proprietary solid-phase synthesis materials and has built a technical platform that integrates high-difficulty oligonucleotide synthesis and impurity separation [3] - Blue Sky Technology plans to invest 1.15 billion yuan to build a GMP/like GMP standard biopharmaceutical industrial park and has established a subsidiary in Sweden to enhance global technical collaboration [3] Group 3: Lianhua Technology - Lianhua Technology is rapidly expanding into the small nucleic acid business, leveraging its established small molecule CDMO system [4] - The global CDMO/CMO market is expected to exceed $120 billion by 2024, with a CAGR of approximately 9.5% [4] - The company has made significant progress in international market expansion and has deepened R&D collaborations with leading global pharmaceutical companies [4]

Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Insights - The new materials sector is a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational nature of the new materials industry as the material basis for other industries [5][15]. Summary by Relevant Sections 1. Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [6] - Recent developments include NVIDIA's announcement of its new AI supercomputing platform, Vera Rubin, which has entered full production. The platform features six independent chips, with the Rubin GPU achieving a peak computing power of 50 Petaflops and a training performance 3.5 times that of its predecessor [7][37]. 2. Aerospace Sector - Focus on PI films, precision ceramics, and carbon fiber [8] - The successful acquisition of a production license for the AS700 manned airship marks a significant milestone for China's aerospace industry, indicating a shift towards standardized and commercialized production [9][10]. 3. New Energy Sector - Focus on photovoltaics, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [10] - A notable development is the introduction of the world's first all-solid-state battery by a Finnish startup, set to enter OEM mass production [11]. 4. Biotechnology Sector - Focus on synthetic biology and scientific services [12] - Beijing's economic development zone has announced measures to support the innovation and development of the synthetic biology manufacturing industry, aiming to establish a globally influential industry cluster by 2028 [13]. 5. Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics [14] - The Guangxi government has issued a plan for green mine construction, aiming for over 90% of large and medium-sized mines to meet green standards by the end of 2028 [15]. 6. Industry Rating and Investment Strategy - The new materials sector is expected to benefit from the catalytic effects of downstream application sectors, gradually entering a prosperous cycle, thus maintaining a "Recommended" rating for the new materials industry [15].